Diagnostic accuracy of osteopontin plus alpha-fetoprotein in the hepatocellular carcinoma: A meta-analysis - 11/03/17

Doi : 10.1016/j.clinre.2017.01.010

Jinwan Li ^a,^{^{1
Contributed equally to this work.}}, Xiaoli Chen ^a,^{^{1
Contributed equally to this work.}} , Meiyu Dai ^a, Shifeng Huang ^b, Jingfan Chen ^b,^⁎ , Shengming Dai ^a,^⁎
^a Medical Science Laboratory, the Fourth Affiliated Hospital of Guangxi Medical University, No. 1 Liushi Road, Liuzhou city, Guangxi Province 545005, China
^b Department of General Surgery, the Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, Guangxi 545005, China

^⁎Corresponding authors.

Sous presse. Épreuves corrigées par l'auteur. Disponible en ligne depuis le Saturday 11 March 2017
Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder

Summary

Objective

Osteopontin (OPN) has been reported as a potential biomarker for diagnosis of hepatocellular carcinoma (HCC) in many inconsistent results. This study demonstrates a systematic meta-analysis for the evaluation on diagnostic accuracy of serum or plasma OPN and alpha-fetoprotein (AFP) alone and combined assays for HCC.

Methods

Relevant literatures were searched in PubMed up to August 2016. The quality of each study was evaluated by QUADAS-2 (quality assessment for studies of diagnostic accuracy). Statistical analysis was performed by Meta-Disc 1.4 and Stata 12.0. The random-effect models were used to estimate pooled sensitivity, specificity and other diagnostic indicators of OPN and/or AFP in HCC.

Results

A total of 14 case-control literatures (15 studies) met the inclusion criteria in this meta-analysis. The respective pooled diagnostic sensitivity and specificity were 0.71 (95% CI: 0.69–0.74) and 0.80 (95% CI: 0.78–0.82) for OPN; 0.61 (95% CI: 0.58–0.63) and 0.92 (95% CI: 0.91–0.94) for AFP; 0.82 (95% CI: 0.79–0.84) and 0.77 (95% CI: 0.74–0.80) for OPN plus AFP. Their area under the curve (AUC) values were 0.8786, 0.8718 and 0.9005, respectively.